Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study.
Much has been learned about the pathophysiological state that underlies the development of increased total body volume and edema in left ventricular failure. Very little, however, is known about the mechanism underlying systemic hypervolemia in patients with isolated right ventricular dysfunction. In this manuscript, we describe our randomized clinical trial to assess the relationship between severity of pulmonary arterial hypertension and neurohormonal activation, total plasma volume and renal function. We assess the role of aldosterone and vasopressin in volume retention in patients with pulmonary arterial hypertension with right ventricular failure. As understanding of the pathogenesis of left ventricular failure has been associated with improved therapies, the better understanding of the mechanisms of isolated right ventricular cardiac failure will also lead to improved patient care.
Division of Renal Disease and Hypertension, University of Colorado Denver, Aurora, Colorado, USA.
Shweta
S
Bansal
David
D
Badesch
Todd
T
Bull
Robert W
RW
Schrier
D000450:Aldosterone / Q000627:therapeutic use*; D006305:Health Status Indicators; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D010865:Pilot Projects; D011651:Pulmonary Artery / Q000187:drug effects*; D012106:Research; D013148:Spironolactone / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*; D014667:Vasopressins / Q000627:therapeutic use*; D018497:Ventricular Dysfunction, Right / Q000517:prevention & control
D000451:Mineralocorticoid Receptor Antagonists; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D013148:Spironolactone; D000450:Aldosterone